

## NH TherAguix

### announces the arrival of Dr. Olivier de Beaumont as Chief Medical Officer

*Meylan, France, September 9<sup>th</sup>, 2022*

NH TherAguix ("NHT"), a French clinical biotech specialized in the development of innovative nanomedicines for the treatment of cancer by radiotherapy, announces today the arrival of Dr. Olivier de Beaumont as Chief Medical Officer from September 2022.

Oncology specialist, Olivier de Beaumont will bring his expertise to NHT clinical development. Especially, based on its preliminary very encouraging Phase 2 results, NHT is deepening its registration strategy. Olivier de Beaumont succeeds Dr. Markus Loeffler who has been on this mission for 3 years. Olivier de Beaumont will be in charge of the company's clinical development strategy, its validation by regulatory authorities and its operational implementation, with a view to register the candidate drug AGuIX<sup>®</sup>. He joins the Management Committee of NHT with Géraldine Le Duc (CEO) and Hervé Brailly (Chairman).

Before joining NHT, Olivier de Beaumont served as Chief Medical Officer at ONXEO, where he was in charge of AsiDNA<sup>®</sup> for 6 years, leading early clinical development program from First in Man to successful Phase 2 proof of concept studies. Olivier de Beaumont previously led several clinical development programs, medical affairs and drug safety, as Senior Vice President at Stallergenes Greer, as Director of Business Development for Europe at Quintiles and as global late phase and pharmacoeconomic programs for Oncology at Aventis.

Olivier de Beaumont is a medical doctor and holds an MBA from ESCP and a Master's in Public Health and Health Economics.

#### **About NH TherAguix ([www.nhtheraguix.com](http://www.nhtheraguix.com)):**

NH TherAguix, headquartered in Meylan (France), is a Biotech clinical development company. Its candidate drug AGuIX<sup>®</sup> has been developed to increase the effectiveness of radiation therapy that affects 60% of cancer patients. By its radiosensitizing effect, AGuIX<sup>®</sup> increases the dose difference between the dose of X-rays received by tumors and received by the surrounding healthy tissues. Its clinical effectiveness is based on a nanometric structuring that allows intravenous injection and the combination of three essential properties to fight tumors: target, image and treat. AGuIX<sup>®</sup> is therefore part of the concept of theranostics, which corresponds to the combination of therapy (radiosensitizing effect) and diagnosis (visible in MRI), and more generally precision medicine.

AGuIX<sup>®</sup> has first been extensively tested in various preclinical models and the results published in high impact publications (>80 papers). The innovation is protected by 15 patent families. As of today the product has been injected in ~100 patients with no safety issues. Results of the First In Human Phase I trial in brain metastases (*NANORAD1, 15 pts/15, France*) so far have confirmed the triple effect: targeting, imaging and treatment and doses safety profile (Verry et al, *Science Advances* 2020, Verry et al. *Radiotherapy & Oncology*, 2021). AGuIX<sup>®</sup> is currently undergoing two Phase II randomized trials in brain metastases using either whole brain radiation therapy, (*NANORAD2, 74 pts/100, 14 clinical centers, France*) or stereo-radiosurgery, (*NANOBRAINMETS, 29 pts/134, Dana Farber Brigham Cancer Center, Boston, USA*). Besides confirmed good tolerance and MRI contrast uptake, Phase 2

results already analyzed are promising when comparing the active arm to the control arm of the trial, allowing the company to consider its registration pathway. In parallel, three other exploratory trials are underway with significant news flow to be delivered Q4-23/Q1-24: a Phase Ib-II trial for pancreatic and lung cancers (*NANOSMART, 18 pts/100, Dana Farber Brigham Cancer Center, Boston, USA*), a Phase Ib-II trial for glioblastoma (*NANOGBM, 2 pts/66, multicentric, Clermont Ferrand, France*), a Phase Ib trial for advanced cervix cancer (*NANOCOL, 12 pts/12, Gustave Roussy, France*).

NH TherAguix was founded in 2015 by two scientists, Géraldine Le Duc (CEO of NH TherAguix since inception) and Pr. Olivier Tillement (Professor of Chemistry at University of Lyon) after 10 years of academic research that led to the invention of AGuIX® and the discovery of its radiosensitizing effect. Altogether, NH TherAguix raised €29M of dilutive and non-dilutive funds, including a €13M A series in 2019, led by Bpifrance with Arbevel, Omnes and Supernova. The management team is composed of Hervé Brailly (Innate Pharma) as Chairman of the board, Olivier de Beaumont as Chief Medical Officer, and Géraldine Le Duc as CEO.

*Géraldine Le Duc*  
**CEO & co-founder**